key: cord-0905369-q6cz88dg
authors: Cohen, Mikhal E; Eichel, Roni; Steiner-Birmanns, Bettina; Janah, Amir; Ioshpa, Maxim; Bar-Shalom, Rachel; Paul, Jefri J; Gaber, Hanaa; Skrahina, Volha; Bornstein, Natan M; Yahalom, Gilad
title: A case of probable Parkinson's disease after SARS-CoV-2 infection
date: 2020-09-16
journal: Lancet Neurol
DOI: 10.1016/s1474-4422(20)30305-7
sha: 515ac59a1eaf735097e3d06cb9b3b5bdfe1f8e9a
doc_id: 905369
cord_uid: q6cz88dg

nan

www.thelancet.com/neurology Vol 19 October 2020

See Online for appendix depression, or rapid eye movement behaviour disorder. He did not report a previous family history of Parkinson's disease, nor had he been exposed to neurotoxins or recreational drugs.

The routine blood tests were unremark able and CSF measures showed 6 white blood cells (83% mono nuclear cells), with normal glucose (62 mg/dL) and protein (43 mg/dL) concentrations (appendix p 1). Anti SARSCoV2 IgG was detected in the serum but not in the CSF, and realtime RTPCR of the CSF was negative for SARSCoV2. CSF and serum were also negative for common neuronal antibodies, including for GABA type B receptors, NMDA receptors, CASPR2, AMPA receptor type 1, AMPA receptor type 2, and LGI1. A brain CT, diffusion and fluidattenu ated inversion recovery sequences on MRI, and an EEG were all nor mal. But a ¹⁸Ffluorodopa (¹⁸FFDOPA) PET scan showed decreased ¹⁸FFDOPA uptake in both puta mens, more apparent on the left side. Addi tionally, mild decreased uptake in the left caudate was also suspected (figure). Genetic testing for mutations in common hotspots of the LRRK2 gene and full gene sequencing of GBA variants were negative. Next Generation Sequencing was done to screen for other genes related to Parkinson's disease (appendix pp 2-4), but this was also negative. We diagnosed parkinsonism, meeting the Movement Disorders Society Unified Parkinson's Disease Rating Scale criteria for the diagnosis of probable Parkinson's disease. 2 We initiated treatment with 0·375 mg extended release prami pexole, once daily, which resulted in a quick improvement according to the patient's subjective impression, as well as in clinical signs.

During his 9 days of hospitalisation, the patient started complaining of tremor in both legs, more on the right side than the left, and of increased urinary frequency. On discharge, he still had unreadable handwriting, hypo mimia, bradykinesia, and cog wheel rigidity, mostly on the right

Parkinson's disease or parkinsonism have been described after infec tions by viruses, such as influenza A, EpsteinBarr virus, varicella zoster, hepa titis C virus, HIV, Japanese enceph alitis virus, or West Nile virus. 1 We report a patient with probable Parkinson's disease, who was diagnosed after severe acute respiratory syndrome corona virus 2 (SARSCoV2) infection.

A 45 year old AshkenaziJewish man was hospitalised in Samson Assuta Ashdod University Hospital (Ashdod, Israel) on March 17, 2020, because of dry cough and muscle pain. A few days before admission, he had also noticed a loss of smell. His symptoms had started on March 11, 2 days after returning to Israel from a weeklong trip to the USA. He might have been exposed to the virus on the flight back to Israel, since he recalled that a passenger sitting behind him was coughing repeatedly. His previous medical history included hypertension, treated daily with 200 mg labetalol, 80 mg valsartan, and 5 mg amlodipine, and asthma, treated with salbutamol sporadically and at admission. He was found positive for SARSCoV2 by use of a realtime RTPCR test after a nasopharyngeal swab was done on the day of admission. His complete blood count and CRP measures were normal (CRP 1·5 mg/L).

During his hospitalisation in the COVID19 ward, the patient had fatigue, shortness of breath, and chest pain without fever, and was treated for 3 days as an inpatient, mostly with salbutamol inhalations as needed for mild asthma symptoms, with no need for systemic medications, oxy gen supplementation, or mech anical ventilation. The patient was then isolated on March 20 in a COVID19 facility. He tested negatively on naso pharyn geal swabs done on March 25 and March 30. However, dur ing the isolation period of 3 weeks, he noticed that his handwriting had changed and become smaller and less readable than previously. He started having difficulties speaking and writing text messages on his mobile phone. He also had episodes of tremor in his right hand. After returning home, he continued to have these symptoms and was eventually admitted to the Department of Neurology, at Shaare Zedek Medical Center (Jerusalem, Israel) about 2 months after ini tially testing positive for SARSCoV2 infection.

On examination, the patient had hypomimia and hypophonic fluent speech. He had moderate cogwheel rigidity in the neck and in the right arm, mild cogwheel rigidity in the left arm, moderate bradykinesia in the right extremities, mild bradykinesia in the left extremities, and no tremor. His gait was slightly slow, with no right arm swing, and the elbow appeared to be in flexion during walking but with normal step length and height. No retropulsion was found on a pull test.

He did not have cognitive decline, shown by a Montreal Cognitive Assessment score of 28 of 30, but his subjective impression was that his cognitive performance was lower than usual. He did not have constipation, side. He was empirically treated with a course of 5 days intravenous high dose methylprednisolone, without any consistent effect. Because of the worsening of tremor in his right extremities, in a followup visit on June 29, biperiden was added at a dose of 2 mg daily, and increased to 4 mg daily after 1 week, which resulted in improvement of the tremor. The mechanism that led to the presumed degeneration of nigro stria tal dopaminergic nerve terminals is unclear. Perhaps a susceptible genetic makeup made our patient vulner able to immunologically mediated mitochondrial injury and neuronal oxidative stress. Another hypothesis could be that the virus causes inflam mation via microglial activation, contributing to protein aggregation and neurodegenera tion. 3 However, the short time inter val between the acute infection and the parkinsonian symptoms makes this hypothesis unlikely. Other researchers have pro posed the socalled multiple hit hypothesis, by which the com bination of toxic stress and an inhibition of neuroprotective responses can lead to neuronal death. 4 Parkinson's disease is often preceded by anosmia, which is a common feature of SARSCoV2 infection. 5 Immune activation in the olfactory system might eventually lead to the misfolding of αsynuclein and the development of Parkinson's disease. 6 This mechanism is supported by postmortem studies, showing increased levels of TNF, 7 IL1, and IL6. 8 Moreover, patients with Parkinson's disease had an elevated CSF antibody response to seasonal coronaviruses, compared with age matched healthy controls. 9 In AshkenaziJewish people with Parkinson's disease, about a third are carriers of either a GBA or a LRRK2 mutation. 10 A genetic analysis for these mutations and 62 other muta tions associated with the disease was negative and our patient had no previous family history of Parkinson's disease. However, we cannot exclude an interaction between other, less frequent mutations and SARSCoV2. The temporal association between the episode of SARSCoV2 infection and parkinsonian symptoms, which appeared during the acute infection, is intriguing. Before his admission to the Department of Neurology, the patient had tested negative for SARSCoV2 on realtime RTPCR on two occasions; however, he was then found positive for antiSARSCoV2 IgG antibodies in serum, but negative for these anti bodies in CSF. Nonetheless, we cannot exclude the possibility that SARSCoV2 entered the CNS, particularly in view of the olfactory involvement and borderline pleocytosis.

Department of Nuclear Medicine (RBS), Shaare Zedek Medical Center

Infectious etiologies of parkinsonism: pathomechanisms and clinical implications

MDS clinical diagnostic criteria for Parkinson's disease

Induction of microglia activation after infection with the nonneurotropic A/CA/04/2009 H1N1 influenza virus

Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease

Anosmia and ageusia: common findings in COVID19 patients

Inflammation and αsynuclein's prionlike behavior in Parkinson's disease-is there a link?

Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease

We declare no competing interests. 

Since the recognition of the severe acute respiratory syndrome coron avirus 2 out break in December, 2019, there are now over 22·1 million COVID19 cases worldwide, with more than 780 220 deaths. Reports of neurologi cal manifestations associated with COVID19 range from mild (head ache, hyposmia, ageusia, myalgia, and fatigue or sleepiness) to severe (encepha lopathy, ischemic and haem or rhagic strokes, seizures, hypoxicischaemic brain injury, and GuillainBarré and other autoimmune syn dromes), 1-3 with prevalence rates rang ing from 6% to 84%. [1] [2] [3] The true prevalence, underlying mechanisms (infectious, autoimmune, secondary to systemic complications), and outcomes of COVID19 neurological mani festations remain a key knowledge gap.Many global initiatives have emerged to address these critical questions. 4 The rapid and parallel implementation of these initiatives in a pandemic has resulted in discrepant data ele ments and definitions of neurological symptoms and signs. Furthermore, fragmented scientific approaches and over lapping consortia, in which centres can contribute data to multiple registries, raise the possibility of double counting in future metaanalysis. All of these factors threaten the scientific rigour and yield of these combined global efforts. To address this issue, the European Academy of Neurology (EAN) and the Neurocritical Care Society (NCS)endorsed Global Consortium Studies of Neurological Dysfunction in